Acarix AB (publ) (ACARIX.ST)
SEK 0.25
(-4.05%)
SEK 0.25
(-4.05%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 62.88 Million SEK | -9.49% |
| 2022 | 69.48 Million SEK | -41.42% |
| 2021 | 118.6 Million SEK | 31.86% |
| 2020 | 89.94 Million SEK | 8.39% |
| 2019 | 82.98 Million SEK | -12.83% |
| 2018 | 95.19 Million SEK | -28.99% |
| 2017 | 134.05 Million SEK | -22.64% |
| 2016 | 173.28 Million SEK | 1012.09% |
| 2015 | 15.58 Million SEK | -14.78% |
| 2014 | 18.28 Million SEK | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q2 | 79.61 Million SEK | -16.92% |
| 2024 Q1 | 95.83 Million SEK | 52.4% |
| 2023 Q1 | 46.37 Million SEK | -33.25% |
| 2023 Q3 | 38.45 Million SEK | -36.27% |
| 2023 Q2 | 60.34 Million SEK | 30.13% |
| 2023 Q4 | 62.88 Million SEK | 63.52% |
| 2023 FY | 62.88 Million SEK | -9.49% |
| 2022 Q4 | 69.48 Million SEK | 22.98% |
| 2022 Q2 | 76.36 Million SEK | -22.3% |
| 2022 Q1 | 98.28 Million SEK | -17.13% |
| 2022 FY | 69.48 Million SEK | -41.42% |
| 2022 Q3 | 56.49 Million SEK | -26.01% |
| 2021 Q1 | 80.97 Million SEK | -9.97% |
| 2021 FY | 118.6 Million SEK | 31.86% |
| 2021 Q2 | 63.71 Million SEK | -21.32% |
| 2021 Q3 | 53.05 Million SEK | -16.73% |
| 2021 Q4 | 118.6 Million SEK | 123.54% |
| 2020 Q1 | 75.7 Million SEK | -8.78% |
| 2020 FY | 89.94 Million SEK | 8.39% |
| 2020 Q2 | 62.93 Million SEK | -16.87% |
| 2020 Q3 | 103.83 Million SEK | 65.0% |
| 2020 Q4 | 89.94 Million SEK | -13.38% |
| 2019 Q4 | 82.98 Million SEK | 41.44% |
| 2019 FY | 82.98 Million SEK | -12.83% |
| 2019 Q3 | 58.67 Million SEK | -17.71% |
| 2019 Q2 | 71.29 Million SEK | -14.77% |
| 2019 Q1 | 83.65 Million SEK | -12.12% |
| 2018 FY | 95.19 Million SEK | -28.99% |
| 2018 Q4 | 95.19 Million SEK | -9.19% |
| 2018 Q1 | 126.82 Million SEK | -5.39% |
| 2018 Q3 | 104.83 Million SEK | -10.19% |
| 2018 Q2 | 116.72 Million SEK | -7.97% |
| 2017 Q2 | 151.09 Million SEK | -4.31% |
| 2017 Q4 | 134.05 Million SEK | -6.52% |
| 2017 FY | 134.05 Million SEK | -22.64% |
| 2017 Q1 | 157.9 Million SEK | -8.88% |
| 2017 Q3 | 143.4 Million SEK | -5.09% |
| 2016 Q1 | - SEK | -100.0% |
| 2016 Q4 | 173.28 Million SEK | 506.21% |
| 2016 Q3 | 28.58 Million SEK | 0.0% |
| 2016 FY | 173.28 Million SEK | 1012.09% |
| 2015 Q4 | 15.58 Million SEK | 0.0% |
| 2015 FY | 15.58 Million SEK | -14.78% |
| 2014 FY | 18.28 Million SEK | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| ADDvise Group AB (publ) | 3.28 Billion SEK | 98.087% |
| ADDvise Group AB (publ) | 3.28 Billion SEK | 98.087% |
| Arcoma AB | 81.96 Million SEK | 23.277% |
| Bactiguard Holding AB (publ) | 682.87 Million SEK | 90.791% |
| BICO Group AB (publ) | 10.19 Billion SEK | 99.383% |
| Boule Diagnostics AB (publ) | 755.1 Million SEK | 91.672% |
| CellaVision AB (publ) | 928.71 Million SEK | 93.229% |
| Clinical Laserthermia Systems AB (publ) | 57.72 Million SEK | -8.937% |
| Chordate Medical Holding AB (publ) | 21.95 Million SEK | -186.416% |
| C-Rad AB (publ) | 404 Million SEK | 84.435% |
| Duearity AB (publ) | 15.14 Million SEK | -315.24% |
| Dignitana AB (publ) | 44.83 Million SEK | -40.269% |
| Episurf Medical AB (publ) | 104.3 Million SEK | 39.709% |
| Getinge AB (publ) | 55.09 Billion SEK | 99.886% |
| Scandinavian Real Heart AB (Publ) | 102.63 Million SEK | 38.732% |
| Iconovo AB (publ) | 128.07 Million SEK | 50.903% |
| Integrum AB (publ) | 164.85 Million SEK | 61.856% |
| Luxbright AB (publ) | 40.68 Million SEK | -54.557% |
| Mentice AB (publ) | 322.52 Million SEK | 80.503% |
| OssDsign AB (publ) | 356.38 Million SEK | 82.355% |
| Paxman AB (publ) | 167.12 Million SEK | 62.373% |
| Promimic AB (publ) | 92.87 Million SEK | 32.292% |
| Qlife Holding AB (publ) | 39.04 Million SEK | -61.051% |
| SciBase Holding AB (publ) | 64.33 Million SEK | 2.254% |
| ScandiDos AB (publ) | 81.47 Million SEK | 22.816% |
| Sectra AB (publ) | 3.21 Billion SEK | 98.042% |
| Sedana Medical AB (publ) | 1.01 Billion SEK | 93.799% |
| Senzime AB (publ) | 433.54 Million SEK | 85.495% |
| SpectraCure AB (publ) | 144.83 Million SEK | 56.582% |
| Stille AB | 804.89 Million SEK | 92.187% |
| Vitrolife AB (publ) | 16.39 Billion SEK | 99.616% |
| Xvivo Perfusion AB (publ) | 2.19 Billion SEK | 97.136% |